UPCC 06518: A Phase 2 Precision Oncology Study of Biomarker-Directed Pembrolizumab-Based Combination Therapy for Advanced Non-Small Cell Lung Cancer
Enrolling By Invitation
99 years or below
All
Phase
2
10 participants needed
1 Location
Brief description of study
To evaluate the clinical activity (as assessed by objective response rate [ORR]) pembrolizumab (MK-3475) in combination with MK-4280 or lenvatinib in study participants with advanced non-small cell lung cancer (NSCLC) without prior systemic treatment for their advanced disease.
Eligibility of study
You may be eligible for this study if you meet the following criteria:
- Conditions: lung cancer
-
Age: 99 years or below
-
Gender: All
Updated on
19 Feb 2024.
Study ID: 831302
If you need help finding a study or have any questions, please contact us at psom-ocr@pobox.upenn.edu
